Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

The Dawn Of A New Era In Cancer Treatment
A new article in Scrip World Pharmaceutical News highlights enormous change in cancer medicine with highly personalised treatments, patient top-up payments in some markets, response-related payments and even refunds when there is no response to a treatment, all driving the future of cancer care worldwide.
generic viagra online
Discovery Of The Cell's Water Gate May Lead To New Cancer Drugs
The flow of water into and out from the cell may play a crucial role in several types of cancer. Scientists at the University of Gothenburg have now found the gate that regulates the flow of water into yeast cells. The discovery, which has been published in the journal PLoS Biology, raises hopes of developing a drug that inhibits the spread and growth of tumours.
News of the day
First Ten-Year Follow-Up Shows That Treatment With AVONEX® Leads To Long-Term Benefits In Early Multiple Sclerosis Patients
Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent of patients taking AVONEX were below an expanded disability status scale (EDSS) score of three. These data were presented as a poster at the Annual American Academy of Neurology (AAN) meeting.
Public Health

Novel Peripheral IV Catheter: Telesso Technologies Wins Popular Science Invention Award

Telesso Technologies Limited (ASX: TEO), a global healthcare company, has announced the FDA-approved guide wire-assisted peripheral IV catheter it is developing with Vascular Pathways, Inc., has been honored with the Popular Science Invention Award. "Telesso is pleased to receive another exciting external validation of this innovative device that may revolutionize peripheral IV placement," said Telesso"s CEO Nelson K. Stacks. "Attempts to start an IV frequently fail, which is frustrating for clinicians, painful for patients and costly to the health care system. The new guide-wire assisted peripheral IV catheter uses a practical design to improve the ability for clinicians to get it right the first time, creating efficiency, enhancing safety, reducing costs, and avoiding the need for re-sticks." A post-market trial is currently comparing patients treated with Telesso"s catheter to the industry"s gold standard device for peripheral IV placement. Data review is expected in Q2-Q3 2009. About the Guide Wire-Assisted Peripheral IV Cathete A peripheral vein is the most common site for insertion of a catheter for short-term diagnostic or therapeutic use. The catheter is placed into the peripheral vein in the arm and is typically passed up inside the vein to a length of 2-3 inches. Telesso"s uniquely-designed guide wire-assisted peripheral IV catheter device uses a first-in-class retractable nitinol guide wire system that is believed to enable easier IV access, reduce common safety risks, significantly lessen patient pain and discomfort, and provide cost savings to facilities by lowering administrative costs associated with failed IV starts. Telesso believes this catheter device is the first clinically meaningful advancement in peripheral IV access since automatic needle retraction catheters and addresses significant unmet needs in peripheral intravenous access. About the Telesso-VPI Agreement Telesso Technologies Limited announced in December 2008 that it entered into a strategic agreement with Vascular Pathways, Inc. (VPI), a private company based in California, to co-develop VPI"s guide wire-assisted device with the funding of the clinical trial and to potentially acquire VPI. Jeff Riley Cytori Therapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009